An investor looks at an electronic board showing stock information at a brokerage house in Shanghai, China July 6, 2018. REUTERS/Aly Song

SHANGHAI, Aug 11 (Reuters) – A growing number of healthcare companies in China are shelving their initial public offering (IPO) plans as its stock exchanges have stepped up scrutiny of the pharmaceutical industry's business practices amid an escalating anti-corruption drive.

China drugmakers axe IPO plans as they face scrutiny in anti-graft drive comes via ChinaTechNews.com.